Deal Watch: GSK To Tap AN2’s Boron Chemistry Approach In Tuberculosis R&D

Scrip regularly covers business development and deal-making activities within the biopharmaceutical industry. Its "Deal Watch" feature provides comprehensive insights, supported by deal intelligence from Biomedtracker. This platform offers regular updates on key agreements and transactions across the biopharma sector.

Recent Highlights from Biopharma Dealmaking

• A Week Is A Long Time In Biotech, Just Ask Galecto
• MeiraGTx Gene Therapy Catches Lilly’s Eye In $475m Pact
• Pfizer Wins Out In Metsera Bidding War
• Bavarian Nordic Future Looks Bright Despite Failed Takeover Bid
• Biopharma Financial Market Recovery Has Legs As M&A Tally Climbs Higher
• Scrip M&A Podcast: What’s Next For Dealmaking In The Obesity Space?
• Lilly Takes Big Step Forward In AI With NVIDIA Partnership
• Third Quarter M&A Dealmaking May Indicate Gradual Return To Normalcy
• BioMarin Looks To Offload Roctavian As Gene Therapy’s Sales Drop
• GSK Expands Respiratory Pipeline With siRNA Pact
• GSK Doubles Down On B7-H3 ADCs
• Novartis Makes Its Biggest Bet In A Decade With $12bn Avidity Deal
• Lilly Broadens Gene Therapy Push With Adverum Acquisition
• Biogen Takes Aim At Amgen’s Tavneos With Vanqua Licensing Pact
• Alkermes To Buy Avadel, Jumpstarting A Move Into Commercial Sleep Market
• Ipsen Boosts Cancer Pipeline With ImCheck Buy

In a significant development, GSK and AN2 Therapeutics reached an agreement on November 10 to collaborate on developing new therapies for tuberculosis. This partnership will leverage the California biotech's innovative boron chemistry approach in their research and development efforts...